Lumos Pharma, Inc.
LUMO · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $35 | $56 | $95 | $99 |
| Short-Term Investments | $1 | $11 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $26 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $4 | $5 | $4 |
| Total Curr. Assets | $40 | $72 | $100 | $128 |
| Property Plant & Equip (Net) | $1 | $0 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | -$0 | -$1 | -$1 |
| Total NC Assets | $1 | $0 | $1 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $41 | $72 | $100 | $129 |
| Liabilities | – | – | – | – |
| Payables | $1 | $0 | $1 | $0 |
| Short-Term Debt | $1 | $0 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $6 | $6 | $4 | $6 |
| Total Curr. Liab. | $7 | $7 | $5 | $6 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $6 | $0 | $6 | $0 |
| Total NC Liab. | $6 | $6 | $6 | $6 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $0 | $1 | $0 |
| Total Liabilities | $13 | $13 | $11 | $12 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $129 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$162 | -$127 | -$96 | -$66 |
| AOCI | -$0 | -$0 | $0 | -$129 |
| Other Equity | $189 | $187 | $185 | $312 |
| Total Equity | $27 | $60 | $89 | $117 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $41 | $72 | $100 | $129 |
| Net Debt | -$34 | -$56 | -$94 | -$98 |